Central European Journal of Medicine

, Volume 9, Issue 5, pp 657–662 | Cite as

Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment

  • Aldona PietrzakEmail author
  • Jerzy Mosiewicz
  • Grażyna Chodorowska
  • Anna Brzozowska
  • Anna Michalak-Stoma
  • Justyna Szumiło
  • Marcin Trojnar
  • Dorota Krasowska
  • Bartłomiej Wawrzycki
  • Kinga Franciszkiewicz-Pietrzak
  • Wojciech Polkowski
  • Torello Lotti
Case Report


The article focuses on the eruption of palmoplantar pustular psoriasis, which was documented in a 53-year-old man diagnosed with prostate cancer with bone metastases. This clinical finding was made during routine hormone therapy and palliative radiotherapy. The local improvement in skin lesions was achieved following administration of topical ointments and the use of UVA 311 nm radiation therapy. The management of prostate cancer in this subject resulted in malaise, onset of diabetes mellitus and increased concentration of serum lipids. Interestingly, a few days after the statin treatment was initiated, the intensive pustule eruption was observed as well as severe pain and burning sensation in the palms and soles. The dermatological treatment led to significant improvement. The patient is still receiving oncological therapy and is monitored by dermatologists on a regular basis.


Psoriasis Prostate cancer Hormone therapy Statin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Paul CF, Ho VC, McGeown C, et al. Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study. J Invest Dermatol. 2003;120:211–216PubMedCrossRefGoogle Scholar
  2. [2]
    Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778–783PubMedGoogle Scholar
  3. [3]
    Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4:579–594PubMedCrossRefGoogle Scholar
  4. [4]
    Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer. 2011;2:145–156PubMedCrossRefGoogle Scholar
  5. [5]
    Muehlenbein MP, Bribiescas RG. Testosteronemediated immune functions and male life histories. Am J Hum Biol. 2005;17:527–558PubMedCrossRefGoogle Scholar
  6. [6]
    Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411–423PubMedCrossRefGoogle Scholar
  7. [7]
    Fitzpatrick F, Lepault F, Homo-Delarche F, Bach JF, Dardenne M. Influence of castration, alone or combined with thymectomy, on the development of diabetes in the nonobese diabetic mouse. Endocrinology. 1991;129:1382–1390PubMedCrossRefGoogle Scholar
  8. [8]
    Harbuz MS, Perveen-Gill Z, Lightman SL, Jessop DS. A protective role for testosterone in adjuvant-induced arthritis. Br J Rheumatol. 1995;34:1117–1122PubMedCrossRefGoogle Scholar
  9. [9]
    Ahmed SA, Penhale WJ. The influence of testosterone on the development of autoimmune thyroiditis in thymectomized and irradiated rats. Clin Exp Immunol. 1982;48:367–374PubMedCentralPubMedGoogle Scholar
  10. [10]
    Fox HS. Androgen treatment prevents diabetes in nonobese diabetic mice. J Exp Med. 1992;175:1409–1412PubMedCrossRefGoogle Scholar
  11. [11]
    Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in theautoantigen-specific T lymphocyte response. J Immunol. 1997;159:3–6PubMedGoogle Scholar
  12. [12]
    Ansar Ahmed S, Young PR, Penhale WJ. Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. J Immunol. 1986;136:143–147PubMedGoogle Scholar
  13. [13]
    Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–593PubMedCentralPubMedCrossRefGoogle Scholar
  14. [14]
    Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol. 2010;71:496–504PubMedCentralPubMedCrossRefGoogle Scholar
  15. [15]
    Norata GD, Cattaneo P, Poletti A, Catapano AL. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. Atherosclerosis. 2010;212:100–106PubMedCrossRefGoogle Scholar
  16. [16]
    Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharideinduced inflammatory response in human endothelial cells. J Clin Endocrinol Metab. 2006;91:546–554PubMedCrossRefGoogle Scholar
  17. [17]
    Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602–612CrossRefGoogle Scholar
  18. [18]
    Komatsu S, Hara N, Ishizaki F, Nishiyama T, Takizawa I, Isahaya E, Kawasaki T, Takahashi K. Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. Prostate. 2012;72:1207–1213PubMedCrossRefGoogle Scholar
  19. [19]
    Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis. 1998;1:307–314PubMedCrossRefGoogle Scholar
  20. [20]
    Ziółkowska E, Biedka M, Żyromska A, Makarewicz R. Psoriasis exacerbation after hormonotherapy in prostate cancer patient — Case report. Rep Pract Oncol Radiother. 2010;15:103–106PubMedCentralPubMedCrossRefGoogle Scholar
  21. [21]
    Honma M, Takahashi H, Horikawa M, Iizuka H. Palmoplantar Pustular Lesions during Ovulation Inducement Therapy: New Insight into the Pathomechanism of Palmoplantar Pustulosis? Dermatology. 2009;218:382–384PubMedCrossRefGoogle Scholar
  22. [22]
    Egesi A, Sun G, Khachemoune A, Rashid RM. Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol. 2010;9:921–927PubMedGoogle Scholar
  23. [23]
    Rajpara AN, Goldner R, Gaspari A. Psoriasis: can statins play a dual role? Dermatol Online J. 2010;16:2Google Scholar
  24. [24]
    Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol. 2007;57:529–531PubMedCrossRefGoogle Scholar
  25. [25]
    Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol. 1988;124:854–855PubMedCrossRefGoogle Scholar
  26. [26]
    Cozzani E, Scaparro M, Parodi A. A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep. 2009;3:60–61PubMedCentralPubMedCrossRefGoogle Scholar
  27. [27]
    Jacobi TC, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol. 2003;149:1305–1306PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Aldona Pietrzak
    • 1
    Email author
  • Jerzy Mosiewicz
    • 2
  • Grażyna Chodorowska
    • 1
  • Anna Brzozowska
    • 3
    • 4
  • Anna Michalak-Stoma
    • 1
  • Justyna Szumiło
    • 5
    • 9
  • Marcin Trojnar
    • 2
  • Dorota Krasowska
    • 1
  • Bartłomiej Wawrzycki
    • 1
  • Kinga Franciszkiewicz-Pietrzak
    • 6
  • Wojciech Polkowski
    • 7
  • Torello Lotti
    • 8
  1. 1.Chair and Department of Dermatology, Venereology and Paediatric DermatologyMedical University of LublinLublinPoland
  2. 2.Chair and Department of Internal MedicineMedical University of LublinLublinPoland
  3. 3.Chair and Department of OncologyMedical University of LublinLublinPoland
  4. 4.St. John’s Cancer CenterLublinPoland
  5. 5.Chair and Department of Clinical PathomorphologyMedical University of LublinLublinPoland
  6. 6.Department of SurgeryMedical University of LublinLublinPoland
  7. 7.Chair and Department of Oncologic SurgeryMedical University of LublinLublinPoland
  8. 8.Chair and Department of Dermatology and VenereologyUniversity of Rome“G. Marconi”RomeItaly
  9. 9.St. John’s Cancer CenterLublinPoland

Personalised recommendations